|
Agent Type:
|
Synthetic; Small molecule; Direct acting;
|
|
Spectrum of activity:
|
Gram-positive & Gram-negative
|
|
Mechanism of action:
|
DNA synthesis inhibitor
|
|
Target Pathogen:
|
Active against vancomycin-resistantStaphylococcus aureus, methicillin-resistant Staphylococcus aureus, quinolone-resistant Staphylococcus aureus, quinolone-resistant Streptococcus pneumoniae, penicillin-resistant Streptococcus pneumoniae, and erythromycin-resistant Streptococcus pneumoniae
|
|
Description:
|
Synthetic compound; a novel non-fluorinated quinolone developed in oral and intravenous formulations; Cardiovascular Safety Evaluation of Nemonoxacin (TG-873870) in Dogs and Monkeys. . A-27. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
By: Chow, C. P.; Tsai, C. Y.; Chen, Y. M.
|
|
Institute where first reported:
|
TaiGen Biotechnology Co.,Taiwan
|
|
Year first mentioned:
|
2007
|
|
Highest developmental phase:
|
Approved in Taiwan
|
|
Development status:
|
Approved
|